Voss, Stephan
Harvard University · Dana-Farber Cancer Institute · Dana-Farber/Harvard Cancer Center
3 papers on CoChatORCID 0000-0002-2092-2219
Most cited papers
- Verified
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial
Davis, K. L., Fox, E., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., et al. (2020) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 337
- Verified
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
Davis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L. (2022) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment
Cited by 75
- Verified
Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children’s Oncology Group ANBL0532 Study
Liu, K. X., Naranjo, A., Zhang, F. F., DuBois, S. G., Braunstein, S. E., Voss, S. D., Khanna, G., London, W. B., Doski, J. J., Geiger, J. D., et al. (2020) · Journal of Clinical Oncology
Neuroblastoma Research and TreatmentsGlioma Diagnosis and Treatment
Cited by 60
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free